Learn

Inflammatory Bowel Disease Research Review Issue 87 with commentary by Dr Alex Barnes.

This review is a unique Australian publication providing topical, relevant and accessible information for health professionals with an interest in Inflammatory Bowel Disease. In essence, the review is a summary of what we consider to be some of the most significant new studies in this area.

Details

In this issue we feature:

-  Noninvasive, microbiome-based IBD diagnosis
-  Guselkumab for moderately to severely active UC
-  Mirikizumab for moderately to severely active CD
-  Filgotinib for moderately to severely active CD
-  Vedolizumab to prevent postoperative CD recurrence
-  Infliximab-azathioprine during steroid tapering for acute severe UC
-  Mucosal healing with vedolizumab in chronic pouchitis
-  Advanced therapies in moderately to severely active UC
-  Durable remission after ileocolic resection for CD
-  Metronidazole or vancomycin for C. difficile infection in IBD

To access this publication please click ‘Enrol Now’ and you’ll be directed to  the publication. Then sign up to Research Review at no cost. You can then login with your email and password. If you require any assistance please email Research Review – trish@researchreview.com.au

This activity is accepted by CPD Home as a Domain 1: Educational Activity - Professional Reading in alignment with the CPD Home Program Guide. 

Disclaimer: Please note, once you click 'Enrol now' you will be leaving the AMA’s CPD Home website and entering a third-party website.